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Abstract
Background: Advances in genetic technology have revealed that variation in the same gene can cause both rare familial
and common sporadic forms of the same disease. Cerebral amyloid angiopathy (CAA), a common cause of symptomatic
intracerebral hemorrhage (ICH) in the elderly, can also occur in families in an autosomal dominant pattern. The majority of
affected families harbor mutations in the Beta amyloid Peptide (Ab) coding region of the gene for amyloid precursor protein
(APP) or have duplications of chromosomal segments containing APP.
Methodology/Principal Findings: A total of 58 subjects with a diagnosis of probable or definite CAA according to validated
criteria were included in the present study. We sequenced the Ab coding region of APP in 58 individuals and performed
multiplex ligation-dependent probe amplification to determine APP gene dosage in 60. No patient harbored a known or
novel APP mutation or gene duplication. The frequency of mutations investigated in the present study is estimated to range
from 0% to 8% in individuals with probable CAA in the general population, based on the ascertained sample size.
Conclusions/Significance: We found no evidence that variants at loci associated with familial CAA play a role in sporadic
CAA. Based on our findings, these rare highly-penetrant mutations are unlikely to be seen in sporadic CAA patients.
Therefore, our results do not support systematic genetic screening of CAA patients who lack a strong family history of
hemorrhage or dementia.
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Introduction
Recent advances in genetic technology have clarified that
variation in the same gene can cause both familial (usually more
severe and/or earlier onset) and sporadic forms of the same disease.
For example, rare highly penetrant sequence variants in several
genes (HNF4A, GCK, TCF1/HNF1A, TCF2/HNF1B) invariably
cause a monogenic disorder known as maturity-onsetdiabetes of the
young (MODY), while common less penetrant variants in the same
genes areriskfactors for multifactorial type2 diabetes. [1] Similarly,
rare and common sequence variants within the ABCC8 gene have
been associated with monogenic disorders (congenital hyperinsu-
linism of infancy), as well as sporadic type 2 diabetes. [2,3]
The effect of more common variants is generally much less
potent than that of rare variants, and as a result, for example, not
all carriers of ABCC8 variants develop diabetes. However,
clustering of common and rare disease-causing variants in a single
gene provides additional insight into pathophysiology, and may
prove crucial for individual risk prediction.
Cerebral amyloid angiopathy (CAA) is characterized by b-
amyloid peptide (Ab) deposition and destruction of the vessel walls
of capillaries, arterioles and small- and medium-sized arteries of
the cerebral cortex, leptomeninges and cerebellum. In its sporadic
form CAA is a common cause of intracerebral hemorrhage (ICH),
[4] MRI-detected white matter hyperintensity (WMH) and
cognitive dysfunction. [5,6] Vascular amyloid, like the amyloid
plaques in Alzheimer disease (AD), is composed chiefly of a 39- to
43- amino acid proteolytic fragment of the b-amyloid precursor
protein (APP). A large body of data links the e2 and e4 alleles of
APOE to CAA susceptibility. [7] Epidemiological data, however,
point to an even larger role for genetic variation as a risk factor for
CAA, suggesting that there are other loci in the genome that
modulate risk. [8]
In addition to occurring as a spontaneous condition in the
elderly, CAA also manifests as a rare familial syndrome in which
manifestations generally develop earlier in life. Most familial forms
of CAA involve mutations within APP. [8–14], and present with
vascular deposition of Ab causing a clinical phenotype akin to
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clinical features. Besides the easily identifiable family inheritance
pattern, familial CAA can be differentiated from sporadic CAA
because of the average earlier age of onset (,55 years) and greater
severity. All known APP mutations associated with CAA cluster
within the Ab-coding region of the gene (exons 16 and 17). [6] In
addition to point mutations within APP, duplication of the APP
locus on chromosome 21 has also been identified in families with
familial early-onset AD and CAA. [15] Functional studies have
clarified that these mutations within APP result in altered b-
amyloid biological properties and subsequent deposition, much
like in sporadic CAA.
Motivated by the close phenotypic and biological overlap
between sporadic and familial CAA, we investigated whether any
of the established rare variants or novel variants in the same
protein region of APP might contribute to susceptibility to sporadic
CAA.
Methods
Ethics Statement
The Institutional Review Board of the Massachusetts General
Hospital approved all aspects of this study, and written informed
consent for participation in the present study was obtained from all
participating subjects or their surrogates.
Patients
Subjects consisted of patients referred to Massachusetts General
Hospital over an eleven year period who qualified for the diagnosis
of probable or definite CAA according to the Boston Criteria. [4]
Application of these criteria allows for reliable diagnosis of CAA in
living subjects in the absence of cortical biopsy specimens, using
clinical and neuroimaging data to assign patients to different
groups, based on the likelihood of CAA pathology being present
(Table 1).
Sequencing of APP Exons 16 & 17
Exons 16 and 17 of APP were amplified using a standard
polymerase chain reaction (PCR) protocol. SNP detection was
performed automatically with the SNP Compare analysis suite
(Broad Institute of MIT and Harvard), which collates and
compares SNP calls from two SNP calling algorithms, PolyDHAN
and PolyPhred. [16] The quality of a given SNP is scored based on
its detectability in each sequencing direction (forward and reverse)
as determined by each SNP calling algorithm, as well as its
estimated false positive rate. SNP Compare estimates false positive
rates for detected variants using data derived from the Interna-
tional HapMap Consortium’s ENCODE resequencing efforts.
[17]
Copy Number Assessment
We used multiplex ligation-dependent probe amplification
(MLPA) (MRC Holland, Amsterdam, Holland) to assess for the
presence of duplication of APP. Genomic DNA from ten
unaffected individuals and one individual with trisomy-21 were
included as negative and positive controls, respectively. Four
synthetic paired probes for APP exons and four paired probes
specific for genes flanking the APP locus were designed. Additional
MLPA probes targeting sequences on chromosomes other than
chromosome 21 were included as internal controls. All APP paired
probe ligation sites were located in the coding regions of the gene.
Probes for regions flanking APP were designed to detect
duplications in genes previously found to show copy number
variation in individuals with autosomal-dominant early-onset
Alzheimer Disease with CAA. [15]
Statistical Analyses
Novel variants and/or duplication of the APP locus in
sequenced patients were used to infer the probability of identical
findings in the general population of sporadic CAA patients by
computing exact confidence limits for binomial proportions based
on available sample size [18]. Findings from our study were
compared to the theoretical binomial distribution (any APP
mutation vs. no APP mutation) in the general population the
study subjects were sampled from, i.e. sporadic CAA patients
diagnosed according to the Boston criteria.
Results
Of the 58 subjects (Table 2), 35 met criteria for probable CAA
on radiographic and clinical criteria alone, while CAA was
pathologically confirmed in 23 individuals (6 from autopsy reports
and 17 from pathology reports from biopsy-obtained tissue). MRI
data for CAA diagnosis was available for 32 (55%) subjects. Of all
enrolled subjects, 13 (22%) had a single ICH before the event
qualifying them for enrollment, while 2 (2%) had an history of
multiple intracerebral bleeds. Five patients (9%) were being
Table 1. Boston criteria for CAA diagnosis.
1. Definite CAA
Full postmortem examination demonstrating:
N Lobar, cortical, or corticosubcortical hemorrhage
N Severe CAA with vasculopathy*
N Absence of other diagnostic lesion
2. Probable CAA with supporting pathology
Clinical data and pathologic tissue (evacuated hematoma or cortical biopsy)
demonstrating:
N Lobar, cortical, or corticosubcortical hemorrhage
N Some degree of CAA in specimen
N Absence of other diagnostic lesion
3. Probable CAA
Clinical data and MRI or CT demonstrating:
N Multiple hemorrhages restricted to lobar, cortical, or corticosubcortical regions
(cerebellar hemorrhage allowed)
N Age $55 years
N Absence of other cause of hemorrhage{
4. Possible CAA
Clinical data and MRI or CT demonstrating:
N Single lobar, cortical, or corticosubcortical hemorrhage
N Age $55 years
N Absence of other cause of hemorrhage{
*As defined in reference 20.
{Other causes of intracerebral hemorrhage include:
N excessive warfarin dosing (INR .3.0)
N antecedent head trauma or ischemic stroke
N CNS tumor
N vascular malformation
N CNS vasculitis
N blood dyscrasia
N coagulopathy.
Note: INR.3.0 or other nonspecific laboratory abnormalities permitted for
diagnosis of possible CAA.
doi:10.1371/journal.pone.0013949.t001
APP and Sporadic CAA
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and dementia was present in 3 (5%) and 2 (3%) individuals
respectively.
Sequencing of exon 16 was successful in 55 patients while
MLPA was completed in 36. No novel variants or known
mutations were identified in exons 16 and 17 and no duplication
of the APP locus or in the four investigated flanking genes
(NCAM2, C21orf42, CYYR1, USP16) was detected. Based on
available sample size, exact confidence limits for binomial
proportions estimate the frequency of mutations investigated in
the present study as ranging from 0% to 8% in individuals with
probable CAA in the general population.
Discussion
We found no evidence that novel variants or established causal
mutations for familial CAA have a role in sporadic CAA. These
data suggest that rare mutations responsible for familial CAA are
of such potency in their effect that they are unlikely to be found in
patients without the familial syndrome. Furthermore, our results
indicate that if APP exons 16 and 17 indeed harbor additional
CAA-causing rare variants, their limited expected frequency in the
sporadic CAA population suggests the overall associated attribut-
able risk is likely to be minimal.
Based on these conclusions systematic genetic screening of CAA
patients lacking a strong family history of hemorrhage or dementia
is not warranted at this time. Familial and sporadic CAA are
unlikely to share individual risk mutations.
Our study has several limitations. Based on previous genetic
findings and functional studies in familial CAA, we only examined
sequenced variation in exons 16 and 17 of APP. It is possible that
variants in other exons or, of course, non-coding regions of APP,
may influence the risk of sporadic CAA. However, current insight
into the metabolism and deposition of b-amyloid suggest that
mutations in exons 16 and 17 are often associated with functional
consequences in Ab properties, something which has not been
described for coding or non-coding variants outside of these exons.
In addition, our sample size was limited by the number of
individuals whose clinical evaluation allowed qualification for the
diagnosis of probable CAA. While systematic autopsy studies
demonstrate that CAA is a common pathological finding in the
elderly, its demonstration during life generally requires MRI or
biopsy, which limits the number of individuals whose eligibility for
studies like ours. [19–21] However, selection of CAA patients
based on manifestation with ICH is likely to enrich our study
cohort with more severe cases, presumably increasing our chance
to observe CAA-associated mutations.
Susceptibility to a vast number of complex diseases is
determined at least in part by the cumulative contribution of
multiple common DNA polymorphisms of small effect. Sequence
variants with large effects, however, may also contribute to
variation in complex traits, such as circulating lipid levels. [22]
Our results do not exclude a role for genetic variation in APP as a
risk factor for sporadic CAA. Indeed, the clinical and biological
overlap between familial and sporadic CAA suggests that there will
be areas of shared genetic risk. Nonetheless, further investigation
of APP variants in sporadic CAA is likely to require substantially
larger samples of both cases of sporadic CAA and unaffected
controls, a scale requiring large-scale multi-center collaboration.
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